SG11201903911UA - Combinations of fgfr4 inhibitors and bile acid sequestrants - Google Patents
Combinations of fgfr4 inhibitors and bile acid sequestrantsInfo
- Publication number
- SG11201903911UA SG11201903911UA SG11201903911UA SG11201903911UA SG11201903911UA SG 11201903911U A SG11201903911U A SG 11201903911UA SG 11201903911U A SG11201903911U A SG 11201903911UA SG 11201903911U A SG11201903911U A SG 11201903911UA SG 11201903911U A SG11201903911U A SG 11201903911UA
- Authority
- SG
- Singapore
- Prior art keywords
- basel
- klybeck
- novartis
- international
- bile acid
- Prior art date
Links
- 229920000080 bile acid sequestrant Polymers 0.000 title abstract 4
- 229940096699 bile acid sequestrants Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101150082429 FGFR4 gene Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 2
- 229940125408 FGFR4 inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111 0 1110101011111 011101 0 011111111111111111111111111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/083603 Al 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: Declarations under Rule 4.17: A61K 31/4545 (2006.01) A61P 35/00 (2006.01) A61K 31/506 (2006.01) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) (21) International Application Number: — as to the applicant's entitlement to claim the priority of the PCT/IB2017/056787 earlier application (Rule 4.17(iii)) (22) International Filing Date: Published: 01 November 2017 (01.11.2017) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,222 02 November 2016 (02.11.2016) US (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). (72) Inventors: FAIRHURST, Robin Alec; c/o Novartis Phar- ma AG, Klybeck, 4002 Basel (CH). GRAUS PORTA, Di- ana; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). KINYAMU-AKUNDA, Jacqueline; c/o Novartis Pharma- ceuticals Corporation, One Health Plaza, East Hanover, — 07936 (US). MAHL, Andreas Joerg; c/o Novartis Phar- ma AG, Klybeck, 4002 Basel (CH). MANENTI, Luigi; c/o = - Novartis Pharma AG, Klybeck, 4002 Basel (CH). WEISS, Andreas; c/o Novartis Pharma AG, Klybeck, 4002 Basel =_ (CH). WOLF, Armin; c/o Novartis Pharma AG, Klybeck, 4002 Basel (CH). WUERSCH, Kuno; c/o Novartis Pharma = AG, Klybeck, 4002 Basel (CH). = Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = (81) — CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, — HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = — = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = _ _ OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = — Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, — GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = _ 1-1 0 en , tD cr) GC O_ 0 (54) Title: COMBINATIONS OF FGFR4 INHIBITORS AND BILE ACID SEQUESTRANTS 1-1 0 (57) : The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, N to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side- C::) effects associated with FGFR4 inhibition therapy.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416222P | 2016-11-02 | 2016-11-02 | |
| PCT/IB2017/056787 WO2018083603A1 (en) | 2016-11-02 | 2017-11-01 | Combinations of fgfr4 inhibitors and bile acid sequestrants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903911UA true SG11201903911UA (en) | 2019-05-30 |
Family
ID=60661908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903911UA SG11201903911UA (en) | 2016-11-02 | 2017-11-01 | Combinations of fgfr4 inhibitors and bile acid sequestrants |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11229643B2 (en) |
| EP (1) | EP3534902B1 (en) |
| JP (2) | JP7394623B2 (en) |
| KR (1) | KR102362648B1 (en) |
| CN (2) | CN109922804B (en) |
| AU (1) | AU2017354082B2 (en) |
| CA (1) | CA3042475C (en) |
| ES (1) | ES2934341T3 (en) |
| IL (1) | IL266293B (en) |
| MA (1) | MA46712A (en) |
| MX (1) | MX387222B (en) |
| PL (1) | PL3534902T3 (en) |
| PT (1) | PT3534902T (en) |
| RU (1) | RU2742033C2 (en) |
| SG (1) | SG11201903911UA (en) |
| WO (1) | WO2018083603A1 (en) |
| ZA (1) | ZA201902744B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6585167B2 (en) | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Use of fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| CN112759593A (en) * | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | Bridged ring-fused aldehyde pyridine derivative and application thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2582652T3 (en) | 2006-02-10 | 2016-09-14 | Genentech, Inc. | Anti-FGF19 antibodies and methods of use thereof |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| EP2124884B1 (en) * | 2006-12-22 | 2019-07-10 | Ironwood Pharmaceuticals, Inc. | Compositions comprising bile acid sequestrants for treating esophageal disorders |
| CL2008000947A1 (en) | 2007-04-02 | 2008-10-10 | Genentech Inc | USE OF A BETA-KLOTHO PROTEIN ANTAGONIST (KLB) TO TREAT DISORDERS ASSOCIATED WITH THE EXPRESSION OR ACTIVITY OF KLB. |
| US8524212B2 (en) * | 2007-10-24 | 2013-09-03 | Mitsubishi Tanabe Pharma Corporation | Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis |
| FR2933702A1 (en) | 2008-07-08 | 2010-01-15 | Sanofi Aventis | SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR |
| WO2010026291A1 (en) | 2008-09-03 | 2010-03-11 | Licentia Ltd. | Materials and methods for inhibiting cancer cell invasion related to fgfr4 |
| US20100330175A1 (en) * | 2009-06-24 | 2010-12-30 | Jobdevairakkam Christopher N | Cross-linked polyallylamine tablet core |
| CA2828890A1 (en) | 2011-04-07 | 2012-10-11 | Genentech, Inc. | Anti-fgfr4 antibodies and methods of use |
| MX347354B (en) | 2011-08-17 | 2017-04-24 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS. |
| SG11201500125QA (en) | 2012-07-11 | 2015-02-27 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| ES2915851T3 (en) * | 2012-12-27 | 2022-06-27 | Ngm Biopharmaceuticals Inc | FGF19 chimeric peptides for use in the treatment of bile acid disorders |
| WO2014105849A1 (en) | 2012-12-28 | 2014-07-03 | Xoma (Us) Llc | Antibodies specific for fgfr4 and methods of use |
| WO2014165287A1 (en) | 2013-03-12 | 2014-10-09 | The Translational Genomics Research Institute | Hybridoma clones and monoclonal antibodies to fibroblast growth factor 4 |
| WO2014145909A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| CN105307657B (en) | 2013-03-15 | 2020-07-10 | 西建卡尔有限责任公司 | Heteroaryl compounds and their uses |
| AR097455A1 (en) | 2013-08-28 | 2016-03-16 | Astellas Pharma Inc | PHARMACEUTICAL COMPOSITION CONTAINING PYRIMIDINE COMPOSITE AS AN ACTIVE INGREDIENT |
| PH12016500676B1 (en) | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| TN2016000115A1 (en) | 2013-10-25 | 2017-07-05 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. |
| WO2015107171A1 (en) | 2014-01-17 | 2015-07-23 | Sanofi | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody |
| AU2015277438B2 (en) * | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016023894A1 (en) | 2014-08-11 | 2016-02-18 | U3 Pharma Gmbh | Human anti-fgfr4 antibody |
| JP6585167B2 (en) * | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Use of fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| US20160115164A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| TWI712601B (en) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | Bicyclic heterocycles as fgfr inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016151501A1 (en) * | 2015-03-25 | 2016-09-29 | Novartis Ag | Pharmaceutical combinations |
| EP3095465A1 (en) * | 2015-05-19 | 2016-11-23 | U3 Pharma GmbH | Combination of fgfr4-inhibitor and bile acid sequestrant |
-
2017
- 2017-11-01 SG SG11201903911UA patent/SG11201903911UA/en unknown
- 2017-11-01 CN CN201780068265.7A patent/CN109922804B/en active Active
- 2017-11-01 CN CN202311453574.XA patent/CN117257800A/en active Pending
- 2017-11-01 MX MX2019005194A patent/MX387222B/en unknown
- 2017-11-01 KR KR1020197015424A patent/KR102362648B1/en active Active
- 2017-11-01 ES ES17812269T patent/ES2934341T3/en active Active
- 2017-11-01 MA MA046712A patent/MA46712A/en unknown
- 2017-11-01 JP JP2019523704A patent/JP7394623B2/en active Active
- 2017-11-01 EP EP17812269.3A patent/EP3534902B1/en active Active
- 2017-11-01 IL IL266293A patent/IL266293B/en unknown
- 2017-11-01 RU RU2019116061A patent/RU2742033C2/en active
- 2017-11-01 CA CA3042475A patent/CA3042475C/en active Active
- 2017-11-01 AU AU2017354082A patent/AU2017354082B2/en active Active
- 2017-11-01 US US16/347,194 patent/US11229643B2/en active Active
- 2017-11-01 PL PL17812269.3T patent/PL3534902T3/en unknown
- 2017-11-01 WO PCT/IB2017/056787 patent/WO2018083603A1/en not_active Ceased
- 2017-11-01 PT PT178122693T patent/PT3534902T/en unknown
-
2019
- 2019-05-02 ZA ZA2019/02744A patent/ZA201902744B/en unknown
-
2021
- 2021-11-10 JP JP2021183688A patent/JP2022033766A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7394623B2 (en) | 2023-12-08 |
| US20200261444A1 (en) | 2020-08-20 |
| CN117257800A (en) | 2023-12-22 |
| BR112019008787A2 (en) | 2019-07-16 |
| CN109922804B (en) | 2023-11-17 |
| CN109922804A (en) | 2019-06-21 |
| KR102362648B1 (en) | 2022-02-11 |
| MX2019005194A (en) | 2019-08-05 |
| EP3534902A1 (en) | 2019-09-11 |
| ZA201902744B (en) | 2021-08-25 |
| WO2018083603A1 (en) | 2018-05-11 |
| AU2017354082A1 (en) | 2019-05-23 |
| RU2742033C2 (en) | 2021-02-01 |
| IL266293A (en) | 2019-06-30 |
| MA46712A (en) | 2019-09-11 |
| IL266293B (en) | 2022-07-01 |
| RU2019116061A3 (en) | 2020-12-04 |
| CA3042475A1 (en) | 2018-05-11 |
| PT3534902T (en) | 2022-12-07 |
| PL3534902T3 (en) | 2023-03-27 |
| MX387222B (en) | 2025-03-18 |
| JP2022033766A (en) | 2022-03-02 |
| RU2019116061A (en) | 2020-12-04 |
| AU2017354082B2 (en) | 2023-07-27 |
| ES2934341T3 (en) | 2023-02-21 |
| EP3534902B1 (en) | 2022-11-23 |
| KR20190082256A (en) | 2019-07-09 |
| JP2019533701A (en) | 2019-11-21 |
| CA3042475C (en) | 2024-01-16 |
| US11229643B2 (en) | 2022-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201907505TA (en) | Low-viscosity, high-concentration evolocumab formulations and methods of making the same | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201908159QA (en) | Dual magl and faah inhibitors | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201903770UA (en) | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |